Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.
BACKGROUND
Dronedarone has been developed for treatment of atrial fibrillation (AF) or atrial flutter (AFL). It is an amiodarone analogue but noniodinized and without the same adverse effects as amiodarone.


OBJECTIVE
This is a review of 7 studies (DAFNE, ADONIS, EURIDIS, ATHENA, ANDROMEDA, ERATO and DIONYSOS) on dronedarone focusing on efficacy, safety and prevention of stroke. There was a dose-finding study (DAFNE), 3 studies focusing on maintenance of sinus rhythm (ADONIS, EURIDIS and DIONYSOS), 1 study focusing on rate control (ERATO) and 2 studies investigating mortality and morbidity (ANDROMEDA and ATHENA).


RESULTS
The target dose for dronedarone was established in the DAFNE study to be 400 mg twice daily. Both EURIDIS and ADONIS studies demonstrated that dronedarone was superior to placebo for maintaining sinus rhythm. However, DIONYSOS found that dronedarone is less efficient at maintaining sinus rhythm than amiodarone. ERATO concluded that dronedarone reduces ventricular rate in patients with chronic AF. The ANDROMEDA study in patients with severe heart failure was discontinued because of increased mortality in dronedarone group. Dronedarone reduced cardiovascular hospitalizations and mortality in patients with AF or AFL in the ATHENA trial. Secondly, according to a post hoc analysis a significant reduction in stroke was observed (annual rate 1.2% on dronedarone vs 1.8% on placebo, respectively [hazard ratio 0.66, confidence interval 0.46 to 0.96, P = 0.027]). In total, 54 cases of stroke occurred in 3439 patients (crude rate 1.6%) receiving dronedarone compared to 76 strokes in 3048 patients on placebo (crude rate 2.5%), respectively.


CONCLUSIONS
Dronedarone can be used for maintenance of sinus rhythm and can reduce stroke in patients with AF who receive usual care, which includes antithrombotic therapy and heart rate control.
Christiansen
Christine Benn
CB
Department of Cardiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark;
Torp-Pedersen
Christian
C
Køber
Lars
L
D000638:Amiodarone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D000077764:Dronedarone; D006801:Humans; D020521:Stroke / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone
Lancet. 1997 May 3;349(9061):1269-76
9142060
N Engl J Med. 2008 Jun 19;358(25):2678-87
18565860
J Cardiovasc Pharmacol. 2003 Feb;41(2):191-202
12548079
Br J Clin Pharmacol. 2007 Dec;64(6):785-91
17662087
Lancet. 1992 Feb 8;339(8789):342-4
1346420
J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5
11117382
Circulation. 1991 Aug;84(2):527-39
1860198
Stroke. 1991 Aug;22(8):983-8
1866765
Am Heart J. 2008 Sep;156(3):527.e1-9
18760136
Arch Intern Med. 2005 May 23;165(10):1185-91
15911734
Circulation. 2009 Sep 29;120(13):1174-80
19752319
N Engl J Med. 2007 Sep 6;357(10):987-99
17804843
Arch Intern Med. 2005 Feb 14;165(3):258-62
15710787
Eur Heart J. 2003 Aug;24(16):1481-7
12919771
Br J Pharmacol. 1995 Oct;116(3):1949-56
8640331
N Engl J Med. 1990 Nov 29;323(22):1505-11
2233931
N Engl J Med. 2009 Apr 30;360(18):1811-3
19403901
J Am Coll Cardiol. 2009 Sep 15;54(12):1089-95
19744618